ABELE, STEFAN,COMBES, STEPHANIE,FUNEL, JACQUES-ALEXIS,HILPERT, KURT,HUBLER, FRANCIS,REICHENBAECHER, KATHARINA,RENNEBERG, DORTE,VON RAUMER, MARKUS
申请号:
NZ59299609
公开号:
NZ592996A
申请日:
2009.10.21
申请国别(地区):
NZ
年份:
2013
代理人:
摘要:
Disclosed herein is a crystalline salt of the compound isobutyric acid (1R*,2R*,4R*)-2-(2-{ [3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino} -ethyl)-5-phenylbicyclo[2.2.2]oct-5-en-2-yl ester wherein said crystalline salt consists of: 1 equivalent of isobutyric acid (1R*,2R*,4R*)-2-(2-{ [5 3-(4,7-dimethoxy-1Hbenzoimidazol-2-yl)-propyl]-methyl-amino} -ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester an acid component consisting of 1 to 2 equivalents of an acid selected from the group consisting of hydrobromic acid, sulfuric acid, maleic acid, fumaric acid, methanesulfonic acid, para-toluenesulfonic acid, benzenesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, and ethanesulfonic acid and 0 to 5 equivalents of water. Said crystalline salt is useful in the treatment or prevention of chronic stable angina, hypertension, ischemia (renal and cardiac), cardiac arrhythmias including atrial fibrillation, cardiac hypertrophy, or congestive heart failure.